Real stories. Real impact. A better world.
GOOD NEWS DAILY
AllAnimalsCommunityEconomyEnvironmentHealthHumanityInnovationScienceWeekly Recap

South Africa opens FuturePharma, a shared facility to move new medicines from lab to production

President Cyril Ramaphosa opened the CSIR's FuturePharma facility in Pretoria on 7 October. The open-access site helps researchers and young companies scale up medicine ingredients, part of a push to cut South Africa's reliance on imported drugs.

By , Editor

· South Africa · 2 min read

Source: The Presidency of South Africa ↗
Share
Clear laboratory glassware, including beakers, flasks and measuring cylinders, on a white bench
Clear laboratory glassware, including beakers, flasks and measuring cylinders, on a white bench. Photo: PublicDomainPictures (Pixabay)

President Cyril Ramaphosa opened FuturePharma, a pharmaceutical development facility at the Council for Scientific and Industrial Research (CSIR) in Pretoria, on 7 October, calling it "a milestone in South Africa's journey towards health sovereignty." The open-access site is meant to help researchers and companies turn laboratory work on medicines into products that can be manufactured.

The facility focuses on active pharmaceutical ingredients (APIs), the substances in a medicine that produce its effect. Researchers, universities and companies can use its equipment and staff for process development, scale-up and technology transfer, according to the Presidency.

Not a drug factory, but a shared step between lab and plant

Ramaphosa was explicit about what the facility is not. He said too many promising South African innovations fail to move from the laboratory into development and commercial production, and that FuturePharma fills the space between the two by offering equipment that is too specialized and expensive for individual researchers, universities and young companies to build on their own.

“The facility should not be understood as a conventional commercial pharmaceutical manufacturing facility.” — Cyril Ramaphosa, President of South Africa

He said its success would be measured by the technologies developed, companies supported and skills built, and that facilities like FuturePharma and established manufacturers such as the vaccine maker Biovac should complement each other. He did not give a cost for the facility or targets for how many projects it will take on.

Small-molecule and biologic ingredients under one roof

In an earlier announcement, the CSIR said FuturePharma is designed to make both small-molecule and biologic APIs, with flexible space for developing processes that combine batch and continuous-flow production, built to current Good Manufacturing Practice (cGMP) standards. Once complete, the facility was to be assessed against those standards and the requirements of the South African Health Products Regulatory Authority, which would allow it to make products for local and international markets.

COVID-19 exposed how much medicine South Africa imports

The project follows the COVID-19 pandemic, which the CSIR said exposed Africa's heavy reliance on imported medical supplies. Rachel Chikwamba, the CSIR's group executive for advanced chemistry and life sciences, said imports of high-value biological medicines for chronic diseases such as diabetes, cancer and heart disease weigh on the country's trade balance, with pharmaceuticals the fifth-largest contributor to the deficit.

"Our intent is to be proactive in pandemic preparedness through innovative medical countermeasures accessible to African populations and beyond at a fraction of the cost," she said.

Ramaphosa tied the facility to a wider plan. He named an emerging national Pharmaceutical Roadmap and the Vaccine Innovation and Manufacturing Strategy, and said the African Union and the Africa Centres for Disease Control and Prevention have put local manufacturing at the center of the continent's health security agenda. FuturePharma, he said, is open to collaboration with researchers, institutions and companies from across Africa. African vaccine research is moving forward on the continent too; in Uganda, the first doses of a Bundibugyo Ebola vaccine were given in a phase 1 trial.

Sources

How we choose and verify sources: editorial policy.

More stories: Health care that reaches people (12) →

Your weekly dose of good news

The 5 biggest positive stories of the week, straight to your inbox. Free, no noise.